A detailed history of Pendal Group LTD transactions in Repligen Corp stock. As of the latest transaction made, Pendal Group LTD holds 465,171 shares of RGEN stock, worth $58 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
465,171
Previous 446,863 4.1%
Holding current value
$58 Million
Previous $83.6 Million 5.81%
% of portfolio
0.65%
Previous 0.81%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 19, 2023

BUY
$162.42 - $220.56 $2.97 Million - $4.04 Million
18,308 Added 4.1%
465,171 $0
Q3 2022

Oct 18, 2022

BUY
$160.42 - $256.21 $71.7 Million - $114 Million
446,863 New
446,863 $83.6 Million
Q1 2022

Apr 25, 2022

SELL
$161.19 - $257.96 $177,309 - $283,756
-1,100 Closed
0 $0
Q4 2021

Jan 18, 2022

BUY
$247.59 - $304.47 $272,349 - $334,917
1,100 New
1,100 $291,000
Q1 2021

May 03, 2021

SELL
$180.37 - $226.26 $401,683 - $503,881
-2,227 Closed
0 $0
Q4 2020

Jan 21, 2021

BUY
$148.08 - $206.57 $329,774 - $460,031
2,227 New
2,227 $427,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Pendal Group LTD Portfolio

Follow Pendal Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pendal Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pendal Group LTD with notifications on news.